Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2008 Financial Results
Date:2/5/2009

Company Advancing Core Lysosomal Storage Disorder Programs to Key Milestones in 2009; Expects Continued Strong Financial Position

CRANBURY, N.J., Feb. 5 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the fourth quarter and full year 2008.

On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.63 per share ($0.55 per share on a non-GAAP basis) for the three months ended December 31, 2008. For the year ended December 31, 2008, on a GAAP basis, the net loss attributable to common stockholders was $1.75 per share ($1.46 per share on a non-GAAP basis). As of December 31, 2008, cash, cash equivalents, and marketable securities totaled $121 million.

"In 2008, we made great strides in advancing our lead clinical development programs for Fabry, Gaucher and Pompe diseases while maintaining a strong financial position. We plan to continue this momentum and believe 2009 will be a transformational year for Amicus, as we are committed to achieving several key milestones and to transitioning into a late-stage biopharmaceutical company," said John F. Crowley, Amicus' president and CEO.

Clinical Program Advancements

Amigal(TM) (migalastat hydrochloride) for the treatment of Fabry disease

In the fourth quarter of 2008, Amicus continued to work closely with the U.S. and E.U. regulatory authorities to advance its lead program, Amigal, into Phase 3 development. As previously announced, the Company plans to initiate Phase 3 development of Amigal for the treatment of Fabry disease in the second quarter of 2009.

In January 2009, the Company announced that the FDA supports a Phase 3 clinical trial comparing Amigal to placebo based on a surrogate primary endpoint of the change in the amount of kidney GL-3, the substrate that accumulates in the cells of Fabry patients. Amicus is continuing discussions with the FDA through a Special Protocol Assessment (SPA) procedure that it commenced in the fourth quarter of 2008 to finalize how the primary endpoint will be measured. The Company is expecting to finalize the protocol in the second quarter of this year.

Based on discussions with the European Medicines Agency (EMEA) in the fourth quarter of 2008, the Company plans to initiate a separate clinical trial designed to evaluate the safety and efficacy of Amigal versus enzyme replacement therapy (ERT) in Fabry patients. Amicus and its partner Shire Human Genetic Therapies, Inc. (Shire HGT) plan additional discussions with the EMEA to finalize the design of this study.

In parallel with the Phase 3 regulatory discussions, 23 of the original 26 patients from the Phase 2 studies continue to be treated in a voluntary extension study to characterize the long-term safety and efficacy of Amigal and to evaluate additional doses and dose regimens. Amicus expects data from this extension study to be available in the first quarter of 2009.

Plicera(TM) (isofagomine tartrate) for the treatment of Gaucher Disease

During the fourth quarter, Amicus also focused on executing its ongoing Phase 2 clinical trial of Plicera in Gaucher disease. This 6-month study is designed to evaluate safety and to demonstrate trends of efficacy, as measured by the standard endpoints in Gaucher disease. Amicus previously reported that target enrollment is expected to be surpassed in the study and the Company expects the results to be available in the third quarter of 2009.

Amicus will continue to work closely with its partner, Shire HGT, to prepare for Phase 3 development of Plicera pending the results of the ongoing Phase 2 trial.

AT2220 (1-deoxynojirimycin HCl) for the treatment of Pompe Disease

Amicus continued to make progress throughout the fourth quarter with its ongoing Phase 2 clinical trial of AT2220 in adult Pompe patients. The trial includes an 11-week treatment period with an optional extension study. The objectives of the trial include the evaluation of the safety and pharmacodynamics of multiple doses and regimens of AT2220. The results of this study are expected to be available in the second half of 2009.

In addition, Amicus is continuing to conduct preclinical animal studies to evaluate the effects of administering AT2220 in combination with ERT. Results announced at the American Society of Human Genetics conference in November 2008 indicate that AT2220 in combination with ERT has the potential to increase the stability and tissue uptake of ERT. Amicus is conducting additional preclinical proof-of-concept studies to determine the feasibility of a combination that may be appropriate for Pompe patients who are not amenable to chaperone monotherapy. Amicus expects to discuss additional results at relevant scientific conferences during 2009.

Preclinical Chaperone Programs

Amicus continues to invest in research and development to assess the potential for applying its versatile chaperone technology platform to the treatment of a broader range of human genetic diseases. As part of this effort, Amicus continues to conduct preclinical studies in Parkinson's disease and is investing in new research aimed at evaluating disease targets for other neurodegenerative and genetic disorders.

2009 Financial Guidance

In 2009, Amicus expects to report approximately $70 million in operating expenses, which it expects to be offset by approximately $50 million in program cost-sharing reimbursements and clinical milestone payments from Shire. The Company's 2009 net cash burn is expected to be approximately $20 million. Amicus anticipates ending 2009 with approximately $100 million in cash.

Shire HGT Collaboration

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire plc, to jointly develop Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders, Amigal, Plicera and AT2220. In this collaboration, valued at up to $440 million including an up front payment and success based clinical and sales milestones and excluding royalties and cost sharing, Shire reimburses world-wide development costs on a 50/50 basis, and in return Shire received rights to commercialize these products outside of the U.S. while Amicus retains all rights to commercialize these products in the U.S. In addition, Amicus leads development operations through the end of Phase 2 clinical trials. The companies then share responsibility for Phase 3 clinical trial development leveraging Shire's significant ex-U.S. regulatory and clinical experience as well as its commercial infrastructure.

Additional Financial Results & Notes

On a reported basis, the net loss attributable to common stockholders for the three months ended December 31, 2008, was $14.2 million as compared to $11.8 million for the same period in 2007. On a non-GAAP basis, the net loss for the three months ended December 31, 2008, was $12.5 million as compared to $10.7 million in the same period in 2007.

Amicus recorded revenue during the fourth quarter of 2008 representing two different revenue streams from the Shire agreement. Upon signing the agreement, Amicus received an upfront payment of $50 million that will be recognized as revenue on a straight-line basis over 18 years from the date of the agreement. In the fourth quarter 2008, Amicus recognized $0.7 million of the Shire upfront payment and $3.7 million of research revenue on reimbursed research and development costs.

The differences between U.S. GAAP and non U.S. GAAP financial results are itemized in Tables 2 through 5 and are primarily due to pre-tax stock compensation expense.

Use of Non-GAAP Financial Measures

Amicus' "non-GAAP net loss" and "non-GAAP diluted net loss per common share" financial measures are defined as reported, or GAAP, net loss and diluted net loss per common share excluding certain items further discussed below. Amicus' management uses these non-GAAP financial measures to establish financial goals and to gain an understanding of the comparative financial performance of Amicus from year to year and quarter to quarter. Accordingly, Amicus believes investors' understanding of Amicus' financial performance is enhanced as a result of disclosing these non-GAAP financial measures. Non-GAAP net loss and diluted net loss per common share should not be viewed in isolation or as a substitute for reported, or GAAP net loss and diluted net loss per common share.

    (1) Stock option expense -- Non-GAAP net loss and diluted net loss per
        common share exclude the impact of the stock option expense recorded
        in accordance with SFAS No. 123R. Amicus believes that excluding the
        impact of expensing stock options better reflects the recurring
        economic characteristics of its business.

    (2) Other items -- Non-GAAP net loss and diluted net loss per common share
        exclude other unusual or non-recurring items that are evaluated on an
        individual basis. Amicus' evaluation of whether to exclude an item for
        purposes of determining its non-GAAP financial measures considers both
        the quantitative and qualitative aspects of the item, including, among
        other things (i) its size and nature, (ii) whether or not it relates
        to its ongoing business operations, and (iii) whether or not Amicus
        expects it to occur as part of its normal business on a regular basis.
        Items excluded for purposes of determining non-GAAP net loss and
        diluted net loss per common share include deemed dividends, preferred
        stock accretion, and changes in the fair value of warrant liability.

Conference Call and Webcast

Amicus Therapeutics will host a conference call and webcast today, Thursday, February 5, 2009, at 5:00 P.M. EST to review financial results and recent developments. Interested participants and investors may access the conference call by dialing 877-675-4756 (U.S./Canada) or 719-325-4870 (international).

An audio webcast and archive can also be accessed via the investor section of the Amicus Therapeutics Web site at http://www.amicustherapeutics.com under Investors: Events and Presentations. Web participants are encouraged to go to the Web site 15 minutes prior to the start of the call to register, download and install any necessary software. After the live webcast, a webcast replay will remain available in the Investors section of the Amicus Therapeutics Web site for 30 days.

A telephonic replay of the call will be available for seven days beginning at 8 P.M. EST. Access numbers for this replay are 888-203-1112 (U.S./Canada) and 719-457-0820 (international); participant code 8627644.

Amicus' press releases are available at www.amicustherapeutics.com

About Amicus Therapeutics

Amicus Therapeutics is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera for the treatment of Gaucher disease and AT2220 for the treatment of Pompe disease.

Amicus has a strategic collaboration with Shire Human Genetic Therapies, Inc., a wholly-owned subsidiary of Shire Limited, to develop and commercialize Amicus' three lead pharmacological chaperone compounds for lysosomal storage disorders. Under the agreement, Shire received commercial rights outside of the United States. Amicus retains all U.S. rights.

Forward-Looking Statements

This press release contains and the accompanying conference call will contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should" and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. The inclusion of forward-looking statements should not be regarded as a representation by Amicus that any of its plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong. They can be affected by inaccurate assumptions Amicus might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing and outcomes of ongoing discussions with regulatory authorities and the potential goals, progress, timing and results of clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the business of Amicus, including, without limitation: the potential inability to reach final agreement with regulatory agencies on the use of a surrogate endpoint and phase 3 trial design for Amigal; the potential that results of clinical or pre-clinical studies indicate that the product candidates are unsafe or ineffective; and, our dependence on third parties in the conduct of our clinical studies. Further, the results of earlier clinical trials may not be predictive of future results. Additionally, with respect to statements regarding projections of the Company's cash position and expected use of cash during 2009, actual results may differ based on market factors, the company's ability to execute its operational and budget plans, and its achievement of milestones and receipt of milestone payments from Shire. Additionally, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2008, and our other public filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Amicus undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

    Table 1
                             Amicus Therapeutics, Inc.
                           (a development stage company)
                       Consolidated Statements of Operations
                                    (Unaudited)
                 (In thousands, except share and per share amounts)

                                                                    Period
                                                                     from
                                                                  February 4,
                                                                     2002
                           Three Months          Twelve Months    (inception)
                              Ended                 Ended             to
                           December 31,          December 31,     December 31,
                         2007       2008       2007        2008       2008
    Revenue:
      Research
       revenue         $1,375     $3,650     $1,375     $12,189    $13,564
      Collaboration
       revenue            409        695        409       2,778      3,187
    Total revenue       1,784      4,345      1,784      14,967     16,751

    Operating Expenses:
      Research and
       development      9,670     13,775     31,074      37,764    127,642
      General and
       administrative   5,284      4,990     15,278      19,666     57,736
      Impairment of
       Leasehold
       improvements         -          -          -           -      1,030
      Depreciation and
       amortization       313        457      1,237       1,493      4,287
      In-process
       Research
       and development      -          -          -           -        418
    Total operating
     expenses          15,267     19,222     47,589      58,923    191,113
    Loss from
     operations       (13,483)   (14,877)   (45,805)    (43,956)  (174,362)
    Other income
     (expenses):
      Interest income   1,789        766      5,135       4,819     12,760
      Interest expense    (79)       (39)      (348)       (218)    (1,648)
      Change in fair
       value of warrant
       liability            -          -       (149)          -       (454)
      Other expense         -          -          -           -     (1,180)
    Loss before
     tax benefit      (11,773)   (14,150)   (41,167)    (39,355)  (164,884)
    Income tax
     benefit                -          -          -           -        695
    Net loss          (11,773)   (14,150)   (41,167)    (39,355)  (164,189)
      Deemed dividend       -          -          -           -    (19,424)
      Preferred
       stock accretion      -          -       (351)          -       (802)
    Net loss
     attributable to
     common
     stockholders    $(11,773)  $(14,150)  $(41,518)   $(39,355) $(184,415)
    Net loss
     Attributable
     to common
     stockholders per
     common share -
     basic and diluted $(0.53)    $(0.63)    $(3.14)     $(1.75)
    Weighted-average
     common shares
     outstanding -
     basic and
     diluted       22,343,974 22,576,561 13,235,755  22,493,803


         See accompanying notes to consolidated financial statements



    Table 2
                             Amicus Therapeutics, Inc.
                Reconciliation of GAAP to non-GAAP Measures for the
       Statement of Operations Information for Three Months Ended December 31,
                                       2008
                                    (Unaudited)
                (In thousands, except share and per share amounts)


                                                   Stock       GAAP as
                                   Non-GAAP     Compensation   Reported
    Income Statement
     Classifications:
    Revenue                          $4,345                     $4,345

    Research and development        (13,112)        $(663)     (13,775)
    General and administrative       (4,025)         (965)      (4,990)
    Depreciation and amortization      (457)                      (457)
    Interest income                     766                        766
    Interest expense                    (39)                       (39)

    Summary:

    Net loss:                      $(12,522)      $(1,628)    $(14,150)

    Net loss per share - basic
     and diluted:                    $(0.55)       $(0.07)      $(0.63)

    Weighted average number of
     shares outstanding:         22,576,561                 22,576,561



    Table 3
                             Amicus Therapeutics, Inc.
                Reconciliation of GAAP to non-GAAP Measures for the
       Statement of Operations Information for Three Months Ended December 31,
                                       2007
                                    (Unaudited)
                (In thousands, except share and per share amounts)

                                                    Stock       GAAP as
                                    Non-GAAP     Compensation   Reported
    Income Statement
     Classifications:
    Revenue                          $1,784                     $1,784

    Research and development         (9,235)        $(435)      (9,670)
    General and administrative       (4,608)         (676)      (5,284)
    Depreciation and amortization      (313)                      (313)
    Interest income                   1,789                      1,789
    Interest expense                    (79)                       (79)

    Summary:

    Net loss:                      $(10,662)      $(1,111)    $(11,773)

    Net loss per share - basic
     and diluted:                    $(0.48)       $(0.05)      $(0.53)

    Weighted average number of
     shares outstanding:         22,343,974                 22,343,974



    Table 4
                             Amicus Therapeutics, Inc.
                Reconciliation of GAAP to non-GAAP Measures for the
       Statement of Operations Information for Year Ended December 31, 2008
                                   (Unaudited)
                (In thousands, except share and per share amounts)


                                                  Stock       GAAP as
                                  Non-GAAP    Compensation    Reported
    Income Statement
     Classifications:
    Revenue                       $14,967                     $14,967

    Research and development      (35,272)       $(2,492)     (37,764)
    General and administrative    (15,711)        (3,955)     (19,666)
    Depreciation and amortization  (1,493)                     (1,493)
    Interest income                 4,819                       4,819
    Interest expense                 (218)                       (218)

    Summary:

    Net loss:                    $(32,908)       $(6,447)    $(39,355)

    Net loss per share - basic and
     diluted:                      $(1.46)        $(0.29)      $(1.75)

    Weighted average number of
     shares outstanding:       22,493,803                  22,493,803



    Table 5
                             Amicus Therapeutics, Inc.
                Reconciliation of GAAP to non-GAAP Measures for the
       Statement of Operations Information for Year Ended December 31, 2007
                                    (Unaudited)
                (In thousands, except share and per share amounts)

                                   Change
                                   in Fair
                                    Value
                                     of      Preferred
                                   Warrant     Stock       Stock      GAAP as
                        Non-GAAP  Liability  Accretion  Compensation  Reported

    Income Statement
     Classifications:
    Revenue              $1,784                                        $1,784

    Research and
     development        (29,480)      $-         $-       $(1,594)    (31,074)
    General and
     administrative     (12,887)                           (2,391)    (15,278)
    Depreciation and
     amortization        (1,237)                                       (1,237)
    Interest income       5,135                                         5,135
    Interest expense       (348)                                         (348)
    Change in fair
     value of warrant
     liability                -     (149)                                (149)
    Preferred stock
     accretion                -                (351)                     (351)

    Summary:

    Net loss:          $(37,033)   $(149)     $(351)      $(3,985)   $(41,518)

    Net loss per share
     - basic and
     diluted:            $(2.80)  $(0.01)    $(0.03)       $(0.30)     $(3.14)

    Weighted average
     number of shares
     outstanding:    13,235,755                                    13,235,755

FOLD -G


'/>"/>
SOURCE Amicus Therapeutics
Copyright©2009 PR Newswire.
All rights reserved


Related biology technology :

1. Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date
2. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
3. Amicus Therapeutics to Present at Lazard Capital Markets Healthcare Conference
4. Amicus Therapeutics Announces Third Quarter 2008 Financial Results
5. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
6. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
7. Amicus Therapeutics Opens Research Facility in San Diego
8. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
9. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
10. Amicus Therapeutics Announces First Quarter 2008 Financial Results
11. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 08, 2016 , ... ... Location: Baruch S. Blumberg Institute at the Pennsylvania Biotechnology Center of Bucks County, ... and The Commonwealth Medical College (TCMC) will hold an open house for participants ...
(Date:2/9/2016)... ... 2016 , ... Tunnell Consulting, Inc. announced that Frédéric Lefebvre has joined the ... acquiring new accounts and work closely with existing Tunnell clients throughout Europe to ensure ... European clients more than 15 years of experience in the pharmaceutical industry, a thorough ...
(Date:2/9/2016)... ... February 09, 2016 , ... PharmApprove ... for the National Organization for Rare Disorders (NORD). Dorman will lead PharmApprove efforts ... are heard throughout the drug regulatory review process. , “Adding Diane Dorman is ...
(Date:2/9/2016)... February 9, 2016 Web deployment ... and protect IP   E-WorkBook 10 from ... out in Germany early this year ... IP. Users will be able to search for information in ... part of the application, to boost collaboration and productivity. ...
Breaking Biology Technology:
(Date:2/3/2016)... GOTHENBURG, Sweden , February 4, 2016 ... Revenues amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth ... Operating profit amounted to SEK 517.6 M (loss: 30.0). Earnings ... from operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% ...
(Date:2/3/2016)... Calif. , Feb. 3, 2016 Vigilant ... Police Department in Missouri ... license plate reader (LPR) data from Vigilant Solutions. ... hit-and-run case in which the victim was walking out of a convenience ... parking space next to his vehicle, striking his vehicle ...
(Date:2/2/2016)... Feb. 2, 2016  BioMEMS devices deployed ... focused on medical screening and diagnostic applications, ... Wearable devices that facilitate and assure continuous ... movement are being bolstered through new opportunities ... signal acquisition coupled with wireless connectivity and ...
Breaking Biology News(10 mins):